Manollia (Lisdexamfetamine Dimesylate)

Lisdexamfetamine is a pro‑drug that is converted in the body to dextroamphetamine. The active molecule increases the release of norepinephrine and dopamine while blocking their reuptake, thereby enhancing neurotransmission in brain circuits that control attention, behavior, and reward processing.

The appropriate dose of Manollia is individualized by a qualified prescriber based on the patient’s age, clinical response, and tolerability. Healthcare professionals determine the starting dose and any subsequent adjustments, following current clinical guidelines and regulatory recommendations.

Safety data for lisdexamfetamine in pregnancy and lactation are limited. Prescribers should weigh potential benefits against possible risks to the fetus or infant and consider alternative therapies when appropriate. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To request Manollia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Manollia is a pro‑drug of dextroamphetamine, offering a smoother onset and longer duration compared with immediate‑release stimulants such as mixed amphetamine salts. Unlike methylphenidate, it is metabolized to an active amphetamine, which may provide different efficacy or side‑effect profiles for some patients.

Manollia should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure it is out of reach of children.

Manollia is taken orally, usually once daily in the morning. The tablet should be swallowed whole with water and can be taken with or without food. Patients should follow the dosing schedule prescribed by their healthcare professional.

Serious risks include cardiovascular events such as hypertension or tachycardia, psychiatric effects like new or worsening psychosis or mania, and the potential for dependence or abuse. Patients should seek immediate medical attention if they experience chest pain, severe anxiety, or any signs of an allergic reaction.

Manollia is contraindicated in individuals with known hypersensitivity to lisdexamfetamine or any amphetamine, those who have taken monoamine oxidase inhibitors within the past 14 days, and patients with severe cardiovascular disease, uncontrolled hypertension, or certain psychiatric conditions. A prescriber must evaluate each patient’s medical history before initiating therapy.